Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilaria Ruffilli

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Best Practice & Research. Clinical Endocrinology & Metabolism|February 16, 2020
Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapyAlessandro Antonelli, Poupak Fallahi, Giusy Elia, et al.
Frontiers in Endocrinology|January 9, 2019
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle AspirationSilvia Martina Ferrari, Concettina La Motta, Giusy Elia, et al.
Oncology Reports|March 9, 2018
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivoSilvia Martina Ferrari, Guido Bocci, Teresa Di Desidero, et al.
Oncology Reports|March 9, 2018
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivoSilvia Martina Ferrari, Guido Bocci, Teresa Di Desidero, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Best Practice & Research. Clinical Endocrinology & Metabolism|February 16, 2020
Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapyAlessandro Antonelli, Poupak Fallahi, Giusy Elia, et al.
Frontiers in Endocrinology|January 9, 2019
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle AspirationSilvia Martina Ferrari, Concettina La Motta, Giusy Elia, et al.
Oncology Reports|March 9, 2018
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivoSilvia Martina Ferrari, Guido Bocci, Teresa Di Desidero, et al.
Oncology Reports|March 9, 2018
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivoSilvia Martina Ferrari, Guido Bocci, Teresa Di Desidero, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Pageof 5